To confirm this observation, later on, we switched the adjuvant from the harsh CFA to AD20Gold+ (nanoemulsion with synthetic MPL) which was designed for human use to study the potential of S1-Fc as the candidate for human COVID-19 vaccine. The gene discussed is PSMD1; the disease is COVID-19.